RedHill Biopharma
RedHill Biopharma to expand COVID-19 opaganib trial to US
February 24, 2021Research and Development COVID-19, RedHill Biopharma
RedHill Biopharma has announced its plans to expand the company’s global Phase II/III study of opaganib in patients with severe …
RedHill enters manufacturing deal with Cosmo for two key products
February 19, 2021Medical Communications RedHill Biopharma
RedHill Biopharma has announced agreements with Cosmo Pharmaceuticals to manufacture two of RedHill’s key products. Cosmo will manufacture Movantik, RedHill’s …
RedHill expands manufacturing capacity for opaganib with Cosmo
January 29, 2021Medical Communications RedHill Biopharma
RedHill Biopharma has announced a manufacturing agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity for opaganib (Yeliva), to address …
FDA approves RedHill Biopharma’s Talicia to combat Helicobacter pylori infection
November 4, 2019Sales and Marketing FDA, RedHill Biopharma, pharma
RedHill Biopharma is celebrating after the FDA chose to award marketing authorisation to Talicia (omeprazole magnesium, amoxicillin and rifabutin) for …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
